Vagus Nerve Stimulation for Inflammation: What Human Research Shows

Vagus nerve stimulation (VNS) may influence inflammation in humans, and some clinical studies have reported lower inflammatory biomarkers and improvements in disease-related outcomes. But “inflammation” is not one condition with one predictable response. What researchers have found depends on the disease being studied, how the vagus nerve is stimulated, and whether the outcome is a biomarker, a symptom, or a clinical measure of disease activity.

That distinction matters when you read about vagus nerve stimulation for inflammation online. A lower CRP, IL-6, or TNF-α can show that an inflammatory signal changed; it does not automatically mean that pain, organ inflammation, or disease severity improved. At the same time, the human evidence is more substantial than the idea that VNS has only been studied in animals. Several human trials, including studies of non-invasive auricular stimulation, have reported measurable inflammatory changes.

Can Vagus Nerve Stimulation Reduce Inflammation?

Yes. Human studies have found that VNS can change inflammatory signaling, including cytokines such as TNF-α, IL-1β, IL-6, and CRP. Some trials have also reported improvements in symptoms, recovery, or disease activity. The strongest clinical evidence is disease-specific rather than a general finding that VNS reduces inflammation in everyone.

The type of VNS matters because implanted cervical VNS, non-invasive cervical VNS, and transcutaneous auricular VNS (taVNS) do not deliver stimulation in the same way. An implanted RA trial tells us something important about vagal neuromodulation, but its results should not be copied directly onto an ear-based device. The reverse is also true: the fact that an auricular trial is non-invasive does not make its findings irrelevant. Several controlled human studies have directly tested taVNS and found changes in inflammatory markers.

How Does the Vagus Nerve Influence Inflammation?

The Inflammatory Reflex Links Neural Signals and Immune Responses

The vagus nerve is part of a two-way communication system between the brain, organs, and immune system. It carries sensory information toward the brain and participates in signals that influence autonomic and immune activity. Researchers use the term inflammatory reflex to describe neural regulation that can help control the intensity of an immune response.

This gives VNS a different starting point from a conventional anti-inflammatory drug. Instead of directly blocking an inflammatory molecule, stimulation changes neural signaling that can influence downstream immune activity. The pathway is biologically plausible and supported by experimental work, while human research is testing how reliably this neural regulation can be translated into clinical effects.

The Cholinergic Anti-Inflammatory Pathway

One mechanism studied in this area is the cholinergic anti-inflammatory pathway. Vagal-related signaling can influence immune cells through acetylcholine and connected neural-immune circuits, helping limit the release of pro-inflammatory cytokines. Much of the pathway was established through experimental research; human studies are now asking whether stimulating the vagus nerve can produce the same type of useful immune modulation in patients.

That is why cytokines matter in VNS research. If stimulation is followed by a change in TNF-α, IL-1β, IL-6, or CRP, researchers have evidence that inflammatory signaling changed. The next question is more practical: did the person also have less disease activity, less pain, better function, or better recovery? Those outcomes do not always move together.

What Does Human Research Show About VNS and Inflammation?

What Have Human Studies Found About Inflammatory Markers?

The human evidence includes several positive findings, particularly in studies of acute inflammation and in some disease-specific trials. A randomized, double-blind, sham-controlled pilot study in 20 people with sepsis found lower serum TNF-α and IL-1β and higher IL-4 and IL-10 after five days of taVNS. The cytokine changes were greater with taVNS than with sham stimulation, while SOFA and APACHE II scores did not differ between groups. The useful conclusion is specific: taVNS changed inflammatory signaling in these patients; the study did not establish a broader clinical treatment effect.

Other controlled studies have reported similar biological signals. In a randomized trial of 52 hospitalized people with COVID-19, seven days of taVNS reduced CRP by 23.9% and IL-6 by 37.7% in the active group, although the study did not find differences across all clinical outcomes. In the NUVISTA randomized trial of 35 patients with large-vessel-occlusion stroke, taVNS produced a different trajectory in IL-6 and aggregate pro-inflammatory cytokines compared with sham, while 90-day functional outcomes were not significantly different.

Newer postoperative research adds another useful piece. In a 120-person randomized trial after thyroid surgery, taVNS was associated with better recovery scores, lower pain and nausea, shorter hospital stay, and lower IL-6 and TNF-α. Here, inflammatory changes appeared alongside clinical recovery measures, giving researchers a stronger basis for asking whether inflammation is part of the pathway connecting stimulation with recovery.

A broader review helps put these individual results in perspective. A 2024 systematic review and meta-analysis covering 36 human VNS studies and 1,135 participants found anti-inflammatory signals in individual reports, but pooled analyses of 26 studies did not show statistically significant overall reductions in TNF-α or IL-6. A subgroup of four long-term studies involving acute inflammation did show a significant reduction in CRP. The review also found substantial heterogeneity and generally limited study quality. Because its literature search and trial-registration follow-up ended in 2023, it does not include several of the newer randomized studies above. The current picture is therefore one of a human biological effect that varies by condition, protocol, and outcome, rather than a simple yes-or-no effect.

Why Do Clinical Studies Report Different Results?

VNS studies are not testing one intervention. Stimulation can be delivered at the neck or ear, invasively or non-invasively, for different durations and at different frequencies and intensities. The participants may have rheumatoid arthritis, sepsis, stroke, postoperative inflammation, or another condition. Those differences change both the biological target and the outcome researchers can reasonably expect to see.

The outcome itself can also change the answer. A study may detect a lower cytokine level without seeing a meaningful change in disease activity. Another may find better pain or recovery scores alongside inflammatory changes. A small pilot may show a promising signal that later becomes weaker in a larger sham-controlled trial.

The 2023 randomized trial of auricular VNS in 113 people with active rheumatoid arthritis is a useful example. At 12 weeks, the primary ACR20 response was 25.0% with active stimulation and 26.9% with sham, with no significant difference. DAS28-CRP also did not differ significantly, although HAQ-DI improved more with active stimulation. The trial results narrow the conclusion: that particular auricular protocol did not demonstrate a significant effect on the trial’s primary clinical endpoint.

Contrast that with the 2026 pivotal RESET-RA trial of an implanted cervical VNS system in 242 people with drug-refractory RA. At three months, 35.2% of the active group achieved an ACR20 response compared with 24.2% of the sham group. The pivotal randomized trial reached its primary endpoint and provides substantially stronger clinical evidence for implanted VNS in this specific RA population.

These results are not contradictory. They are answers to different questions. The auricular RA trial tested one non-invasive protocol in one population. RESET-RA tested a specific implanted system in a different, highly selected group with difficult-to-treat RA. Reading them together is more informative than asking whether “VNS works” in the abstract.

Which Inflammatory Conditions Have Been Studied With Vagus Nerve Stimulation?

VNS has been studied in several inflammatory and immune-related conditions, but the evidence is not equally mature across them.

Rheumatoid arthritis has the clearest disease-specific clinical evidence. Earlier implanted studies reported reductions in TNF and improvements in RA disease activity, and the 2026 pivotal trial confirmed a significant clinical benefit for a defined group of drug-refractory patients. In 2025, the FDA approved the SetPoint System for adults with moderately to severely active RA who had an inadequate response, loss of response, or intolerance to specified biologic or targeted synthetic DMARDs. That is a specific regulatory indication, not an approval of VNS as a general anti-inflammatory treatment.

Crohn’s disease has also produced encouraging findings. Small studies of implanted VNS have reported lower disease activity, CRP, fecal calprotectin, and inflammatory cytokines, including a 16-person prospective study in treatment-refractory disease. A later long-term follow-up of the original cohort reported sustained benefit in some patients, but the prospective study and subsequent follow-up remain small proof-of-concept evidence rather than definitive evidence for routine treatment.

Other conditions show why the evidence needs to be read at the disease level. In a small sham-controlled SLE trial, taVNS improved pain and fatigue, while most measured inflammatory mediators did not change significantly. In inflammatory bowel disease, a pediatric proof-of-concept trial of taVNS reported reductions in fecal calprotectin and symptom improvement in some participants. These findings are promising, but they do not establish one common VNS effect across autoimmune and inflammatory diseases.

For readers who want the rheumatic-disease evidence in one place, our 2026 review of VNS in rheumatic diseases breaks down the human studies by condition and stimulation method.

Is Non-Invasive Vagus Nerve Stimulation as Effective as Implanted VNS for Inflammation?

They are related approaches, but the evidence cannot be ranked by device type alone. Implanted VNS currently has the strongest disease-specific clinical evidence in rheumatoid arthritis because it has been tested in larger, sham-controlled trials and now has a defined FDA indication. Non-invasive VNS has a different evidence base, with growing human data from auricular and cervical stimulation.

The practical difference is straightforward. Implanted VNS places an electrode directly on the cervical vagus nerve and requires surgery. Non-invasive approaches stimulate through the skin, either at the neck or at auricular regions associated with vagal innervation. Because the stimulation route, dose, and device differ, evidence should be matched to the intervention being considered.

For taVNS specifically, the human evidence is no longer limited to feasibility studies. Controlled trials have reported changes in CRP, IL-6, TNF-α, and other inflammatory measures in several settings. A 2026 feasibility study of home-based respiratory-gated taVNS in active RA found high adherence and preliminary reductions in pain and TNF-α, while noting that its single-arm design was not powered to establish efficacy. This is a growing research area, not an evidence-free one.

At the same time, a positive taVNS biomarker study should not be treated as equivalent to the implanted RESET-RA trial. The right comparison is not “ear versus implant”; it is whether the study population, stimulation method, protocol, and outcome match the question you are trying to answer.

What Should You Know Before Using VNS for Inflammation?

Start with the condition you want to address. If you have a diagnosed inflammatory disease, look for human studies in that disease and check whether they used implanted VNS, cervical stimulation, or taVNS. That will tell you much more than a general statement that “VNS reduces inflammation.”

Then look at the outcome. If your goal is to change CRP or another biomarker, prioritize studies that measured it directly. If your main concern is pain, fatigue, function, sleep, or recovery, a biomarker result alone cannot tell you whether you should expect the same change. Human VNS research shows that biological and clinical outcomes can move together, but they can also separate.

For someone looking for a non-invasive, ear-based routine, ZenoWell Luna uses auricular taVNS and includes a Medit mode designed to support relaxation. Some ZenoWell users report better sleep and changes they associate with pain or inflammation after continued use. These experiences are personal reports, not clinical proof that Luna treats inflammation, but they show how people are incorporating vagus nerve stimulation into regular relaxation and recovery routines.

Safety depends on the stimulation method. A systematic review of 177 taVNS studies involving 6,322 participants found no higher overall adverse-event risk with active stimulation than with controls; the most commonly reported effects were ear pain, headache, and tingling. Implanted VNS has a different risk profile because it involves surgery and an implanted device. Follow the instructions for the specific device, and discuss use with a clinician if you have a medical condition or implanted electronic device that could affect stimulation.

Frequently Asked Questions

Can Vagus Nerve Stimulation Lower CRP or Other Inflammatory Markers?

Yes. Human studies have reported lower CRP, IL-6, TNF-α, and other inflammatory markers after VNS, including taVNS. The effect is not uniform across studies, so a biomarker change is best read as evidence that inflammatory signaling changed rather than as proof that an inflammatory disease has improved.

Does Vagus Nerve Stimulation Treat Autoimmune Diseases?

VNS is being studied in several autoimmune diseases, and implanted VNS now has an FDA-approved indication for a defined group of adults with moderately to severely active rheumatoid arthritis. Studies in lupus, inflammatory bowel disease, and other conditions are encouraging but remain more limited or condition-specific.

Can an Ear-Based Vagus Nerve Stimulator Reduce Inflammation?

Yes, auricular VNS has produced inflammatory biomarker changes in human trials, including studies of sepsis, COVID-19, stroke, and postoperative recovery. The research supports taVNS as a legitimate area of human investigation; whether a particular consumer device produces the same effect depends on its stimulation site, parameters, and protocol.

Can Relaxation Exercises Replace Vagus Nerve Stimulation?

No. Breathing and relaxation exercises can support autonomic regulation and stress management, while VNS uses electrical neuromodulation. They can be complementary approaches, but they are not interchangeable with a clinical VNS protocol or a prescribed treatment for an inflammatory disease.